Develops oncolytic viral immunotherapies to treat cancer, harnessing the power of viruses to attack tumor cells.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. The company's leading candidate, CAN-2409, is in various stages of clinical trials: Phase II for pancreatic cancer, Phase III for prostate cancer, and Phase II for lung cancer. Additionally, CAN-2409 has completed Phase Ib/II trials for high-grade glioma, demonstrating its broad potential in oncology.
Another promising therapy in Candel Therapeutics' pipeline is CAN-3110, currently in Phase I clinical trials for the treatment of recurrent glioblastoma. The company's innovative approach extends to the enLIGHTEN Discovery Platform, an HSV-based discovery platform that leverages human biology and advanced analytics to develop new viral immunotherapies for solid tumors. This platform underscores Candel's commitment to harnessing cutting-edge technology in the fight against cancer.
Originally known as Advantagene, Inc., the company rebranded to Candel Therapeutics, Inc. in November 2020 to better reflect its mission and expanding scope. Incorporated in 2003 and headquartered in Needham, Massachusetts, Candel Therapeutics is dedicated to advancing cancer treatment through its robust pipeline and groundbreaking research, aiming to provide new hope for patients battling various forms of cancer.